| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 83831-0144-05 | 83831-0144 | Etoposide | Avopef | 100.0 mg/5mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Apr 1, 2026 | In Use | |
| 00015-3404-20 | 00015-3404 | etoposide phosphate | ETOPOPHOS | 100.0 mg/1 | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Jun 1, 2009 | Apr 30, 2021 | No Longer Used |
| 55390-0493-01 | 55390-0493 | Etoposide | Etoposide | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Sep 28, 2001 | May 31, 2013 | No Longer Used | |
| 63323-0104-25 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Jul 18, 2001 | In Use | |
| 00703-5656-01 | 00703-5656 | Etoposide | Toposar | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Aug 1, 1996 | Jan 31, 2024 | No Longer Used |
| 68001-0265-23 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 68001-0265-27 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
| 44567-0507-01 | 44567-0507 | Teniposide | Teniposide | 10.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Apr 30, 2013 | In Use | |
| 68001-0683-27 | 68001-0683 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Dec 1, 2025 | In Use | |
| 00015-1911-13 | 00015-1911 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | Oct 31, 2017 | No Longer Used | |
| 70020-1911-01 | 70020-1911 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | In Use | ||
| 70020-1910-01 | 70020-1910 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | In Use | ||
| 00015-1910-12 | 00015-1910 | Ixabepilone | Ixempra | Chemotherapy | Antitumor Antibiotic | Epothilones | Intravenous | Oct 16, 2007 | Oct 31, 2017 | No Longer Used | |
| 84043-0200-30 | 84043-0200 | Vepdegestrant | VEPPANU | 200.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, cereblon/CRBN | Oral | May 1, 2026 | In Use | |
| 71332-0007-30 | 71332-0007 | Vepdegestrant | VEPPANU | 100.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | Jun 16, 2026 | In Use | |
| 71332-0008-30 | 71332-0008 | Vepdegestrant | VEPPANU | 200.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | Jun 16, 2026 | In Use | |
| 84043-0100-30 | 84043-0100 | Vepdegestrant | VEPPANU | 100.0 mg/1 | Hormonal Therapy | Proteolysis Targeting Chimera (PROTAC) | ER, Cereblon/CRBN | Oral | May 1, 2026 | In Use | |
| 72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 00310-0075-95 | 00310-0075 | Camizestrant | ETCAMAH | 75.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Sep 4, 2026 | In Use | |
| 72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 00310-0075-01 | 00310-0075 | Camizestrant | ETCAMAH | 75.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Sep 4, 2026 | In Use | |
| 00002-1717-28 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Oct 16, 2025 | In Use | |
| 00002-1717-56 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Oct 15, 2025 | In Use | |
| 00002-1717-61 | 00002-1717 | Imlunestrant | Inluriyo | 200.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ER⍺ | Oral | Nov 13, 2025 | In Use | |
| 72607-0100-00 | 72607-0100 | tazemetostat | TAZVERIK | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | EZH2 | Oral | Jan 23, 2020 | Apr 30, 2029 | In Use |
Found 12611 results — Export these results
Home